Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIUVO-2 adjuvant therapy in high-risk adrenocortical carcinoma
NL-OMON61735Phase 3Not yet recruiting
- Sponsor
- Akademiska sjukhuset
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in adrenal cancer (ACC) comparing Mitotane alone with Mitotane + etoposide + cisplatin (2 arms). Primary endpoint: Recurrence-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
mitotaneetoposidecisplatin
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on NL-OMON61735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61735.